Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 6, 1996, Pages 848-855

  Drexler, Anne P ^a   Micklas, James M ^a   Brooks, Robert R ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Azimilide; Canine; Class III; Myocardial infarction; Sotalol; Ventricular arrhythmias

Indexed keywords

AZIMILIDE; SOTALOL;

ACUTE HEART INFARCTION; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; DOGS; ELECTROCARDIOGRAPHY; HEART; HEMODYNAMIC PROCESSES; IMIDAZOLES; IMIDAZOLIDINES; INFUSIONS, INTRAVENOUS; MALE; MYOCARDIAL INFARCTION; PIPERAZINES; SOTALOL;

EID: 0029820094     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199612000-00016     Document Type: Article

References (43)

1. Tatla DS, David BC, Malloy KJ, Moorehead TJ. In vitro electrophysiology of NE-10064, a novel and highly selective class III antiarrhythmic agent [Abstract]. FASEB J 1993;7:A107.
2. ks in canine ventricular myocytes: effects of NE-10064 (azimilide) [Abstract]. Circulation 1994;90:1-146.
3. Fermini B, Jurkiewicz NK, Jow B, et al. Frequency-dependent effects of NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents [Abstract]. Biophys J 1995;68:A37.
4. Zhang Z, Boutjdir M, Brooks RR, Chen L, El-Sherif N. Characterization of azimilide effects on ion currents of the repolarization phase [Abstract]. Biophys J 1995;68:A111.
5. Mcintosh MA, Tanira M, Pacini D, Kane KA. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia. J Cardiovasc Pharmacol 1994;23:653-7.
6. + currents in human atrial and ventricular myocytes [Abstract]. Circulation 1995;92:1-575.
7. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-71.
8. + currents in cardiac cells [Abstract]. Biophys J 1994;66:A326.
9. Brooks RR, Carpenter JF, Miller KE, Maynard AE. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Proc Soc Exp Biol Med 1996;212:84-93.
10. Miller KE, Decker GE, Brittain D, Carpenter JF, Brooks RR. The class III antiarrhythmic NE-10064 suppresses ouabain-induced arrhythmias in guinea pigs [Abstract]. Can J Physiol Pharmacol 1994;72:82.
11. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachyarrhythmia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993;22:810-8.
12. Parterson E, Holland K, Eller BT, Lucchesi BR. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction: a conscious canine model of sudden coronary death. Am J Cardiol 1982;50:1414-23.
13. Karagueuzian HS, Fenoglio JJ, Weiss MB, Wit AL. Protracted ventricular tachycardia induced by premature stimulation of the canine heart after coronary artery occlusion and reperfusion. Circ Res 1979;44:833-46.
14. Michelson EL, Spear JF, Moore EN. Electrophysiologic and anatomic correlates of sustained ventricular tachyarrhythmias in a model of chronic myocardial infarction. Am J Cardiol 1980;45:583-90.
15. Patterson E, Gibson JK, Lucchesi BR. Postmyocardial infarction reentrant ventricular arrhythmias in conscious dogs: suppression by bretylium tosylate. J Pharmacol Exp Ther 1981;216:453-8.
16. Todt H, Krumpl G, Krejcy K, Raberger G. Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs. J Cardiovasc Pharmacol 1992;19:341-8.
17. Katoh H, Ogawa S, Furuno I, et al. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther 1990;253(3):1077-82.
18. Reiser HJ, Sullivan ME. Antiarrhythmic drug therapy: new drugs and changing concepts. Fed Proc 1986;45:2206-12.
19. Ruskin JN, DiMarco JP, Garan H. Electrophysiologic observations and selection of long term antiarrhythmic therapy. N Engl J Med 1980;303:607-13.
20. Josephson ME, Horowitz LN, Spielman SR, Greenspan AM. Electrophysiologic and hemodynamic studies in patients resuscitated from cardiac arrest. Am J Cardiol 1980;46:948-55.
21. Borggrefe M, Haverkamp W, Shenasa M, Hindricks G, Breithardt G. How to evaluate class-III antiarrhythmic drug efficacy clinically - the benefits and shortcomings of the invasive approach. J Cardiovasc Pharmacol 1992;20:S32-40.
22. Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol 1992;19:256-63.
23. Chézalviel F, Weissenburger J, Guhennec C, et al. Antiarrhythmic effect of a sotalol mexiletine combination on induced ventricular tachycardia in dogs. J Cardiovasc Pharmacol 1993;21:212-20.
24. Wichter T, Borggrefe M, Haverkamp W, Xu C, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease - results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86:29-37.
25. Gonzalez R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 1988;12(6):1568-72.
26. Drexler AP, Micklas JM, Brooks RR. Effects of intravenously administered NE-10064 on programmed electrical stimulation (PES)-induced ventricular arrhythmias in anesthetized infarcted dogs [Abstract]. FASEB J 1993;7:A97.
27. D'Alonzo AJ, Butterfield JL, Drexler AP, Sergio SL. Comparison of the effects of intravenous LNC-834, a new antiarrhythmic agent, and quinidine in canine models of arrhythmia. J Cardiovasc Pharmacol 1990;16:506-17.
28. Fishbein MC, Meerbaum S, Rit J, et al. Early phase of acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;101:593-600.
29. Bailey BJR. Tables of the Bonferroni t statistic. J Am Stat Assoc 1977;72:469-78.
30. Black SC, Chi LG, Mu DX, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther 1991;258:416-23.
31. Zuanetti G, Corr PB. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping. J Pharmacol Exp Ther 1991;256:325-34.
32. Wellens HJJ, Brugada P, Stevenson WG. Programmed electrical stimulation: its role in the management of ventricular arrhythmias in coronary heart disease. Prog Cardiovasc Dis 1986;29:165-80.
33. Mason JW, Winkle RA, Swerdlow CD, Rasmussen K, Ross DA, Griffin JC. Pharmacologic therapy of ventricular tachycardia and the role of electrophysiologic study. In: Masoni A, Alboni P, eds. Cardiac electrophysiology today. London: Academic Press, 1982:315-23.
34. Patterson E, Lynch J, Lucchesi BR. Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol. J Pharmacol Exp Ther 1984;230:519-26.
35. Katoh H, Ogawa S, Furuno I, et al. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther 1990;253(3):1077-82.
36. Lynch JJ, Heaney LA, Wallace AA, Gehret JR, Selnick HG, Stein RB. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1990;15:764-75.
37. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992;58:107-15.
38. Gomoll AW, Bartek MJ. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur J Pharmacol 1986;132:123-35.
39. Gomoll AW, Lekich RF, Bartek MJ, Comereski CR, Antonaccio MJ. Comparability of the electrophysiologic responses and plasma and myocardial tissue concentrations of sotalol and its d stereoisomer in the dog. J Cardiovasc Pharmacol 1990;16:204-11.
40. Lynch JJ, Lucchesi BR. How are animal models best used for the study of antiarrhythmic drugs? In: Hearse D, Manning A, Janse M, eds. Life-threatening arrhythmias during ischemia and infarction. New York: Raven Press, 1987:169-96.
41. Abdollah H, Brennan FJ, Jimmo S, Brien JF. Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias. Can J Physiol Pharmacol 1991;69:812-7.
42. Brooks RR, Butterfield JL. The class III antiarrhythmic NE-10064 increases QTc interval with minor hemodynamic effects in anesthetized dogs [Abstract]. Can J Physiol Pharmacol 1994;72(suppl 1):79.
43. Horowitz LN, Greenspan AM, Rae AP, Kay HR, Spielman SR. Proarrhythmic responses during electrophysiologic testing. Am J Cardiol 1987;59:45-8E.